We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Evox Therapeutics

News List

University of Oxford links up with Evox Therapeutics pharmatimes
November 19, 2020
The University of Oxford’s Harrington Rare Disease Centre has entered a strategic collaboration agreement with Evox Therapeutics focused on rare diseases within the Department of Paediatrics.
Lilly signs up for access to Evox' tech in R&D deal pharmatimes
June 16, 2020
Evox Therapeutics has signed a collaboration deal with Eli Lilly centred on brain/CNS disorders, which could net the latter around $1.2 billion in development, regulatory and commercial milestone payments.
Evox and Takeda sign deal to collaborate on rare disease treatments europeanpharmaceuticalreview
April 02, 2020
In an $882 million deal, Evox and Takeda will partner to develop and manufacture treatments and drug delivery systems for rare diseases.
Takeda enters rare disease alliance with Evox Therapeutics pharmaceutical-technology
March 30, 2020
Takeda Pharmaceutical has entered a multi-target alliance with biotechnology company Evox Therapeutics to develop protein replacement and mRNA therapies for rare diseases.